Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Isomalto-oligosaccharide has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
IMO is used in protein bars as a bulk sweetener and binder that raises fibre content on the panel while keeping texture workable. The cited work compared the combined bar with a carbohydrate control, so the two ingredients cannot be separated. The pairing is a formulation choice with a performance comparison attached, not evidence of a nutrient interaction.
The two are fermented at different rates and in different regions of the colon, inulin more proximally and IMO variably depending on how much of it resists digestion. Blending them spreads fermentation across a longer stretch of bowel. The cited study was in animals, so read the transit finding as mechanistic support rather than a human outcome.
The alpha-1,6 bonds in IMO resist human pancreatic amylase but are accessible to several colonic bacteria including bifidobacteria. That is the whole basis of the synbiotic pairing. Note that a meaningful fraction of commercial IMO is digestible in the small intestine, so how much substrate actually arrives depends on the specific product's degree of polymerisation.
Resistant starch ferments slowly and reaches the distal colon, while the fermentable share of IMO is used earlier. Combining them gives a broader fermentation profile than either alone. This is substrate reasoning from established carbohydrate chemistry, not a tested combination in people.
Psyllium is viscous and largely unfermented, so it works by holding water and adding stool bulk. IMO's fermentable fraction works by feeding bacteria. Combining a bulking fibre with a fermentable one covers both routes, and it can moderate the gas that a purely fermentable fibre produces.
Brush-border alpha-glucosidases hydrolyse a substantial share of commercial IMO before it reaches the colon, which is why analytical fibre content and physiological fibre behaviour diverge for this ingredient. Added glucosidase-containing enzyme blends push that share higher. The practical effect is less material arriving as fermentable substrate and more absorbed as glucose.
IMO is used as the carbohydrate half of synbiotic formulas, supplying substrate to the delivered strain. The pairing is common in commercial products and reviewed in the cited source. How much benefit depends on the product's actual non-digestible fraction, which varies widely between suppliers.
Because a share of IMO is hydrolysed to glucose in the small intestine, products marketed as low-glycaemic fibre can still raise blood glucose more than the label implies. Anyone tracking glucose response should count that fraction. The relevant caution here is about IMO itself rather than any true interaction with chromium.
Nothing specific on file for Isomalto-oligosaccharide. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 8 we read for Isomalto-oligosaccharide. The full linked list is below.
2 sources behind our Isomalto-oligosaccharide verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.